However, the high frequency of PSMA-negative CTCs in patients with PSMA-positive primary tumors detected in our study might be responsible for a lack of response to PSMA-targeting therapies in subpopulations of metastatic tumor cells. This evidence concerns the gene FOLH1 and neoplasm.